WAKEFIELD, Mass. – Curaleaf Holdings, Inc. (CSE: CURA /OTCQX: CURLF), a leading vertically integrated cannabis operator in the United States, today announced it has been granted final approval by the Massachusetts Cannabis Control Commission to open the first adult-use retail dispensary on Cape Cod.
The retail store will be located at 170 Commercial Street in the heart of Provincetown. Curaleaf will work with the Commission to schedule post-final inspections and open the adult use location in early 2020. The company opened its first adult-use retail location in Oxford, Massachusetts in November, 2019.
“As one of the largest cannabis companies in the United States, we are proud to be based right here in Massachusetts and to be expanding our presence across the Commonwealth,” said Curaleaf CEO Joseph Lusardi. “Providing high quality and reliable products to patients and customers in our home state of Massachusetts as well as across the country is important to us.”
“Cultivating wellness is our mission and we’re excited to become a part of this important community where we expect to create over 30 jobs and get involved with many of the local charities and initiatives that are important to the Outer Cape,” said Curaleaf Massachusetts President Patrik Jonsson.
The company also plans to open another adult use retail location in Ware, MA in 2020. Curaleaf currently employs 65 people at its national headquarters in Wakefield, MA and another 145 employees at its local Massachusetts operations, which also includes a medical-only facility in Hanover, MA. Over the past year, Curaleaf has grown to become one of the largest cannabis companies in the United States under the leadership of CEO Joseph Lusardi, a Massachusetts native.
About Curaleaf Holdings
Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) (“Curaleaf”) is a leading vertically integrated multi-state cannabis operator in the United States. It is a high-growth cannabis company with a national brand known for quality, trust and reliability. The company is positioned in highly populated, limited license states, and currently operates in 12 states with 51 dispensaries, 14 cultivation sites and 13 processing sites. Curaleaf has the executive expertise and research and development capabilities to provide leading service, selection, and accessibility across the medical and adult-use markets, as well as in the CBD category through its Curaleaf Hemp brand.
